ADTX · As filed with the SEC
Aditxt income statement, by quarter
The statement as Aditxt presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations (Unaudited) · USD, except per-share amounts
| USD, except per-share amounts | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025† 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Sales | 12,159 | 425† | 748 | 1,004 | 1,018 | 3,175† |
| Cost of goods sold | 9,291 | 456† | 732 | 1,005 | 734 | 71,005† |
| Gross profit | 2,868 | (31)† | 16 | (1) | 284 | (67,830)† |
| OPERATING EXPENSES | ||||||
| General and administrative expenses $0 and $0 in stock-based compensation, respectively | 3,317,648 | 4,124,992† | 2,462,561 | 5,039,036 | 4,348,274 | 4,784,119† |
| Research and development $0 and $10,000 in stock-based compensation, respectively | 1,047,083 | 548,556† | 672,045 | 764,327 | 1,209,205 | 695,952† |
| Sales and marketing $0 and $0 in stock-based compensation, respectively | — | (3,995)† | 6,040 | 349,031 | 50,920 | 103,132† |
| Total operating expenses | 4,364,731 | 4,669,553† | 3,140,646 | 6,152,394 | 5,608,399 | 5,583,203† |
| NET LOSS FROM OPERATIONS | (4,361,863) | (4,669,584)† | (3,140,630) | (6,152,395) | (5,608,115) | (5,651,033)† |
| OTHER INCOME (EXPENSE) | ||||||
| Interest expense | (27,136) | (299,778)† | (176,527) | (47,352) | (157,499) | (37,998)† |
| Interest income | 280 | (62,306)† | 183,631 | 78,566 | 288 | 323† |
| Amortization of debt discount | (24,687) | (60,000)† | (234,167) | (1,212,246) | (200,284) | (272,965)† |
| Gain (loss) on note exchange agreement | — | — | — | — | — | 0† |
| Change in fair value of derivative liabilities | (11,800,798) | 228† | 162 | 980 | 13,145 | — |
| Change in fair value of Evofem warrants | 25,004 | 358,413† | 2,511,781 | (63,211) | — | — |
| Impairment of Evofem F-1 Preferred Stock | — | (764,290)† | (23,001,919) | — | — | — |
| Credit loss on Evofem notes | — | — | (350,000) | — | — | — |
| Total other expense | (11,827,337) | (561,667)† | (21,067,039) | (1,243,263) | (344,350) | 103,861† |
| Net loss before income taxes | (16,189,200) | (5,231,251)† | (24,207,669) | (7,395,658) | (5,952,465) | (5,547,172)† |
| NET LOSS | (16,189,200) | (5,231,251)† | (24,207,669) | (7,395,658) | (5,952,465) | (5,547,172)† |
| Deemed Dividends | — | — | — | — | — | 0† |
| NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST | (241,475) | (529,572)† | (162,264) | (138,850) | (242,156) | (320,544)† |
| NET LOSS ATTRIBUTABLE TO ADITXT, INC. & SUBSIDIARIES | (15,947,725) | (6,088,929)† | (24,045,405) | (7,256,808) | (5,710,309) | (5,226,628)† |
| Net loss per share, basic (in Dollars per share) | (790.49) | — | (548.78) | (3.45) | (8.12) | — |
| Net loss per share, diluted (in Dollars per share) | (790.49) | — | (548.78) | (3.45) | (8.12) | — |
| Weighted average number of shares outstanding during the period, basic (in Shares) | 20,174 | — | 43,816 | 2,101,701 | 703,666 | — |
| Weighted average number of shares outstanding during the period, diluted (in Shares) | 20,174 | — | 43,816 | 2,101,701 | 703,666 | — |
| COMPREHENSIVE LOSS: | ||||||
| Net Loss | (16,189,200) | — | — | — | — | — |
| Other Comprehensive Income: | ||||||
| Change in fair value of Evofem note receivable | 107,805 | — | — | — | — | — |
| TOTAL COMPREHENSIVE LOSS | (16,081,395) | — | — | — | — | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.